Cationic Lipid Composition for High-Transfection Low-Toxicity Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cationic lipid compounds for delivering biologically active substances face challenges in safety, efficacy, and specificity, with increased complexity leading to toxicity and limited clinical application, particularly for nucleic acid therapeutics.
Innovation Solution
Development of novel cationic lipid compounds, such as YK-305, YK-310, YK-312, YK-319, and YK-318, with distinct chemical structures that enhance intracellular transfection efficiency, reduce cytotoxicity, and improve mRNA expression and duration in animals, while minimizing liver toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cationic lipid compounds are used for delivering biologically active substances, then delivery capability is achieved, but toxicity increases and safety deteriorates
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the length and saturation of fatty acid chains (R1 and R2 groups), the structure of the G3 group, and the charge density. These parameter changes result in novel cationic lipid compounds with improved safety profiles and reduced toxicity while maintaining delivery functionality.
Solution Approach 2:
The patent creates composite lipid structures combining different fatty acid chains (R1 and R2 groups with specific carbon lengths and saturation levels) with a central cationic head group (G3 group). This composite approach allows optimization of both delivery capability and safety by integrating multiple structural elements with complementary properties.
2Productivity
If cationic lipid compounds are used to deliver nucleic acids, then transfection efficiency improves, but cell survival rate decreases
Solution Approach 1:
The patent optimizes parameters including the carbon chain lengths (R1: C6-25, R2: C12-25), saturation levels, and the specific structure of the G3 group (HO(CH2)2N(R3)CH2CH(OH)CH2—) to achieve high transfection efficiency while maintaining cell viability. The balanced charge density and hydrophobicity ratios are critical for this optimization.
3Reliability
If lipid nanoparticle complexity is increased to improve delivery, then delivery specificity improves, but manufacturing complexity and toxicity increase
Solution Approach 1:
The patent divides the cationic lipid molecule into distinct functional segments: the R1 and R2 fatty acid chains (hydrophobic region), the central carbon backbone, and the G3 cationic head group (hydrophilic region). This segmentation allows independent optimization of each region's properties while simplifying the overall synthesis process compared to complex multi-component lipid nanoparticles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipid compounds demonstrate significantly improved cell transfection efficiency, reduced cytotoxicity, and sustained mRNA expression in animals, surpassing existing compounds by up to 1,300 times in transfection efficiency and 30% higher cell survival rates, with reduced liver toxicity.
Implementation Method 1
compositions, liposomes and liposome complexes (lipoplexes) containing a cationic lipid as delivery carriers effectively deliver biologically active substances, such as small molecule drugs, polypeptides, proteins and nucleic acids, into cells and/or intracellular compartments
Implementation Method 2
facilitate the delivery of therapeutic and/or prophylactic agents such as nucleic acids to cells
Implementation Method 3
Nucleic acid therapeutics face great challenges due to low cell permeability and high susceptibility to degradation of certain nucleic acid molecules, including RNA
Data Source
AI summary
Provided in the present invention are long-acting low-toxicity novel cationic lipid compounds, which are compounds shown as formula (I), or N-oxides, solvates, pharmaceutically acceptable salts or stereoisomers thereof. Further provided are a composition comprising the compounds and the use thereof for the delivery of therapeutic or prophylactic agents.